CureVac Shares Surge 33.42% Amid Strategic Developments
By ATTN Desk · Editorial oversight: Sean Han
CureVac N.V. (NASDAQ: CVAC)
Introduction
CureVac N.V. is a clinical-stage biopharmaceutical company developing messenger RNA (mRNA)–based medicines. Founded in 2000 and headquartered in Tübingen, Germany, CureVac utilizes proprietary RNA technology to create prophylactic vaccines and therapeutic agents.
Corporate Structure
- Employees: 1,001–5,000 (LinkedIn)
- Headquarters: Tübingen, Germany
- Global Sites: Netherlands, Belgium, Switzerland, USA
- Key Executive:
- Alexander Zehnder, M.D., Chief Executive Officer
- Major Shareholders (as of May 6, 2022):
- dievini Hopp BioTech holding GmbH & Co. KG and affiliates: approximately 46% ownership
Recent Developments and News
- Stock Performance (2025-06-12)
- Closing price: $5.43
- Daily change: +33.42%
- Volume: 1,970,262 shares
- SEC Filings
- 2025-05-20: Form 6-K reporting first quarter 2025 financial results and business update
- 2025-05-23: Form 6-K announcing Annual General Meeting on 2025-06-24
- Collaborations
- 2022-06-XX: GSK licensing agreement restructured; CureVac received €400 million upfront and up to €1.05 billion in milestones
- 2024-04-16: Co-development and licensing agreement with MD Anderson Cancer Center for mRNA-based cancer vaccines
- Pipeline Shifts
- After Phase III efficacy results for CVnCoV showed 47% (2021-06), CureVac discontinued CVnCoV and refocused on developing second-generation vaccines in collaboration with GSK
Financial and Strategic Analysis
| Metric | Value | Date |
|---|---|---|
| Market Capitalization | $1.004 billion | 2025-06-05 |
| Revenue (TTM) | $523.7 million | 2025-06-05 |
| Net Income (TTM) | $180.66 million | 2025-06-05 |
| EPS (TTM) | $0.91 | 2025-06-05 |
| Trailing P/E | 4.90× | 2025-06-05 |
| Total Cash | $438.33 million | 2025-06-05 |
| Total Debt/Equity | 5.78% | 2025-06-05 |
- Strategic Focus
- Diversification into oncology and rare diseases
- Development of an “RNA printer” for rapid decentralized vaccine production (CEPI grant, 2019)
- Advancement of a second-generation mRNA vaccine platform in collaboration with GSK
Market Position and Industry Context
- Sector: Biotechnology (mRNA therapeutics and vaccines)
- Competitors: Moderna, BioNTech, Sanofi, Johnson & Johnson
- Key Partners:
- GSK (influenza & COVID-19 vaccines)
- MD Anderson (cancer vaccines)
- Bill & Melinda Gates Foundation (infectious disease vaccines)
- Boehringer Ingelheim, Sanofi Pasteur, Genmab, CEPI, IAVI
- Exchange: NASDAQ (Ticker: CVAC)
- Korean Name: 큐어백
tl;dr
On June 12, 2025, CVAC shares rose 33.42% to $5.43 on NASDAQ. CureVac filed a Form 6-K on May 20, 2025, reporting Q1 2025 results, and another on May 23, 2025, announcing its AGM for June 24, 2025. Ongoing partnerships include the 2022 GSK licensing agreement and the April 16, 2024, MD Anderson cancer vaccine collaboration. The company continues to develop its second-generation mRNA platform, with upcoming clinical and milestone readouts in oncology and infectious disease programs.